amfAR 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...678910111213141516...2021»
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Hakko Kirin, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR, Aimovig (erenumab) / Amgen, Novartis
    Review, Journal:  A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. (Pubmed Central) -  Feb 23, 2021   
    An overview of the therapeutic GPCR-antibody target landscape and the diversity of current therapeutic programs is provided along with summary case studies for marketed antibody drugs or those in advanced clinical studies. Antibodies in early clinical studies and the emergence of next-generation modalities are also highlighted.Expert opinion: The GPCR-antibody pipeline has progressed significantly with a number of technical developments enabling the successful resolution of some of the challenges previously encountered and this has contributed to the growing interest in antibody-based therapeutics addressing this target class.
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Eh, Leronlimab better (Twitter) -  Feb 21, 2021   
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Clinical, Journal:  CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14. (Pubmed Central) -  Feb 17, 2021   
    Antibodies in early clinical studies and the emergence of next-generation modalities are also highlighted.Expert opinion: The GPCR-antibody pipeline has progressed significantly with a number of technical developments enabling the successful resolution of some of the challenges previously encountered and this has contributed to the growing interest in antibody-based therapeutics addressing this target class. Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19 and they form the basis for ongoing randomized clinical trials.
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Approve leronlimab! (Twitter) -  Feb 10, 2021   
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Pro140 do more now (Twitter) -  Feb 9, 2021   
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    [VIRTUAL] CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition () -  Feb 7, 2021 - Abstract #HIVR4P2021HIVR4P_366;    
    Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19 and they form the basis for ongoing randomized clinical trials. These results support the efficacy of leronlimab as PrEP, with the potential development of long-acting leronlimab to improve drug adherence.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Antibodies to watch in 2021. (Pubmed Central) -  Jan 28, 2021   
    Despite the pandemic, 10 antibody therapeutics had been granted the first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan...Based on the information publicly available as of November 2020, 44 antibody therapeutics are in late-stage clinical studies for non-cancer indications, including 6 for COVID-19, and marketing applications for at least 6 (leronlimab, tezepelumab, faricimab, ligelizumab, garetosmab, and fasinumab) are planned in 2021...Of these 44, marketing application submissions for 13 may be submitted by the end of 2021. *Note added in proof on key events announced during December 1-21, 2020: margetuximab-cmkb and ansuvimab-zykl were approved by FDA on December 16 and 21, 2020, respectively; biologics license applications were submitted for ublituximab and amivantamab.
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Enrollment open, Enrollment change:  Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis (clinicaltrials.gov) -  Jan 26, 2021   
    P2,  N=60, Recruiting, 
    *Note added in proof on key events announced during December 1-21, 2020: margetuximab-cmkb and ansuvimab-zykl were approved by FDA on December 16 and 21, 2020, respectively; biologics license applications were submitted for ublituximab and amivantamab. Not yet recruiting --> Recruiting | N=90 --> 60
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Leronlimab? Anyone? (Twitter) -  Jan 15, 2021